Vogenx Inc’s (NASDAQ:VOGX) Quiet Period Will Expire Tomorrow

Vogenx’s (NASDAQ:VOGX) quiet period will expire on Monday, September 21st. Vogenx had issued 6,250,000 shares in its initial public offering on August 12th. The total size of the offering was $81,250,000 based on an initial share price of $13.00. During Vogenx’s quiet period, insiders and underwriters involved in the IPO are restricted from issuing any earnings forecasts or research reports for the company because of SEC regulations. Following the expiration of the company’s quiet period, it’s expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.

Analysts Set New Price Targets

VOGX has been the subject of a number of research analyst reports. WBB Securities started coverage on shares of Vogenx in a research note on Wednesday, September 2nd. They issued a “speculative buy” rating and a $42.00 price target for the company. Wall Street Zen upgraded shares of Vogenx to a “hold” rating in a research report on Saturday, August 22nd. Finally, JonesTrading started coverage on shares of Vogenx in a report on Tuesday, September 1st. They issued a “buy” rating and a $55.00 target price on the stock. One investment analyst has rated the stock with a Strong Buy rating and one has issued a Buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Strong Buy” and a consensus target price of $48.50.

Vogenx Stock Performance

Shares of NASDAQ:VOGX opened at $32.50 on Friday. Vogenx has a 52-week low of $12.95 and a 52-week high of $38.41.

Vogenx (NASDAQ:VOGX) last announced its earnings results on Thursday, September 17th. The company reported ($0.07) earnings per share (EPS) for the quarter.

Vogenx Company Profile

Vogenx, Inc was a biotechnology company focused on the discovery and development of novel therapies for inflammatory and metabolic diseases. Its research activities centered on small-molecule drug candidates intended to address conditions associated with chronic inflammation and immune-system dysfunction.

The company’s lead investigational compound was VGX-1027, an orally administered candidate studied for its potential anti-inflammatory and immunomodulatory effects. Publicly available information describes research applications involving diseases such as diabetes and other inflammatory disorders, although the company’s development programs were not established as widely marketed commercial products.

Vogenx was based in the United States and operated as a development-stage biopharmaceutical company.